Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CSNK1E | P49674 | 9/20 | 0.42 |
| ▸ | CSNK1D | P48730 | 6/20 | 0.42 |
| ▸ | CDK9 | P50750 | 3/20 | 0.40 |
| ▸ | CCNT1 | O60563 | 2/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | SLC34A1 | Q06495 | 2/20 | 0.37 |
| ▸ | SQOR | Q9Y6N5 | 1/20 | 0.37 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | AKT1S1 | Q96B36 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26645523 | 1.00 | CSNK1E (0.42) | CSNK1ECSNK1DCDK9CCNT1GRIA1 | |
| SCHEMBL30623060 | 0.89 | CCNT1 (0.43) | CSNK1ECSNK1DCDK9CCNT1BTK | |
| SCHEMBL30622428 | 0.86 | JAK3 (0.45) | CSNK1ECSNK1DBTKAKT1AKT1S1 | |
| SCHEMBL26644977 | 0.86 | JAK3 (0.45) | CSNK1ECSNK1DBTKAKT1AKT1S1 | |
| SCHEMBL30622798 | 0.85 | CSNK1D (0.46) | CSNK1ECSNK1DCDK9CCNT1GRIA1 | |
| SCHEMBL26645620 | 0.85 | CSNK1D (0.46) | CSNK1ECSNK1DCDK9CCNT1GRIA1 | |
| SCHEMBL30622780 | 0.85 | CDK9 (0.34) | CDK9CCNT1GRIA1BTKSLC34A1 | |
| SCHEMBL26645177 | 0.85 | BTK (0.40) | CDK9CCNT1BTKALK | |
| SCHEMBL30622787 | 0.85 | BTK (0.40) | CDK9CCNT1BTKALK | |
| SCHEMBL30623143 | 0.85 | CSNK1E (0.48) | CSNK1ECSNK1DBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519265-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | Bayer Aktiengesellschaft (DE) | 2025-03-12 | — | — | EP | disclosed |
| WO-2023213882-A1 | IRREVERSIBLE MUTEGFR INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 2023-11-09 | — | — | WO | disclosed |